: Speaker List

Speaker View

Below is a listing of all sessions the speaker is scheduled to present.

Daniella Kranjac

Enterprise Project Leader

GE Healthcare Lifesciences

Speaker Bio

Daniella is the Enterprise Projects Leader within GE Healthcare Life Sciences, a global business within GE Healthcare focused on platform and turn key solutions for vaccines, biodefense and blood plasma production. The Enterprise Projects team provides biopharma equipment, consumables, services and training & education for biopharma customers and ministries of health globally through tailored end-to-end solutions. Prior to her current role, she held the position of Senior Strategic Marketing Leader for GE Healthcare's ReadyToProcessTM product platform. Previously, Daniella was a co-founder of WAVE Biotech, LLC, and involved in the characterization, commercialization and product development of the WAVE Bioreactor. As Vice President, Global Sales & Marketing for WAVE, she led integration efforts upon the acquisition of WAVE by GE Healthcare. She has held research positions in environmental remediation at Cytec and cell culture at Schering-Plough Corporation. Daniella has a B.E. degree in Chemical Engineering from Stevens Institute of Technology, and is currently an Executive MBA candidate at New York University Stern School of Business.

Have a Question?

You can pose a question to the speaker by clicking on the "Suggest a Question" icon at the end of the session title. Appropriate questions will be answered during the session as time permits (not all questions will be answered).
Wednesday, March 30, 2011
Conference Program
Suggest A Question for this Session
Pandemic Preparedness and the Manufacturing of an Emergency Vaccine: What Role can Single Use Systems Play?
Room: 1E15 ~ 2:00 pm - 3:30 pm (Wednesday, March 30, 2011)
The panel will approach the manufacturing of emergency vaccines from three angles followed by discussion with the audience to identify the most suitable, and economic solution for various scenarios.

The baculovirus production technology can support safe and expeditious vaccine production and provides an attractive alternative to the current egg-based influenza vaccine (TIV) manufacturing process. Protein Sciences Corporation was initially awarded a $34.5 million contract in June 2009 for an 18 month period from the U.S. Department of Health and Human Services to further develop this technology for the production of recombinant influenza vaccines for pandemic preparedness with the contract recently extended for another two year period.

The manufacturing process for FluBlok/PanBlok, a recombinant protein based influenza vaccine including the combination of single- and multi-use equipment in the current process will be described.

Possible scenarios for establishing surge capacity range from warm base manufacturing facilities (ready to go when they need to), to facilities used for the production of other products that can be rapidly deployed when needed through a hybrid approach, to fully disposable factories. The panel will evaluate advantages, and disadvantages of each scenario from a financial, regulatory, and engineering perspective.
Daniella Kranjac - Enterprise Project Leader, GE Healthcare Lifesciences
Kim Nelson - Director, Strategic Consulting, CRB Consulting Engineers
Manon Cox - President & CEO, Protein Sciences Corporation
Reed Exhibitions
  • Pharmaceuticals
  • Biologics
  • Generics
  • Contract Services
ConferencePath System © 2004 - 2015 ConferencePath & MasseyMedia. All Rights Reserved.